02 July 2024
02 July 2024
The assets are projected to contribute revenues in the range of $13m to $15m from the closing date through 31 December 2024.
The XSense system is cleared for a wide range of medical fields, including general surgery, dermatology, thoracic surgery.
The acquisition will strengthen Alcon’s position in the glaucoma space.
Data showed that integrating SoftVue with screening mammography significantly improved cancer detection in women with dense breasts.
The solution is designed to streamline the evaluation process for organs by providing real-time delivery of biopsy results.
With data still showing that ethnic minorities account for less than 40% of US trial populations, there is an urgent need to improve diversity in clinical research.
An IDE from the FDA will facilitate the company to start human trials.
As part of the pilot, 23andMe will offer 5,000 of its premium members a blood biomarker panel through Nightingale’s Remote Health Check.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
